Expert Interview
A Second Look: Discussing the potential of JNJ-1802, a first-in-class oral antiviral in development by Johnson & Johnson for the prevention of dengue fever.
Ticker(s): JNJInstitution: UNITAID & Institute of Human Virology, Nigeria
- Project Director, HIV Selg Testing in Africa and Asia Project (STAR) where he coordinates international project funded by UNITAID. Previously, he was the Director Strategic Information at the Institute of Human Virology of Nigeria (IHVN).
- Medical doctor, research physician, data scientist, project management specialist with expertise in infectious disease; over 10 years clinical and programmatic experience designing, implementing and monitoring interventions addressing quality of TB, HIV and vaccine preventable diseases including surge interventions for epidemic control.
- Experience in the use of protease inhibitor for the treatment of HIV, Herpes zooster and mostly recently SARS-CoV-2.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
